Search | Clinical Trials Finder

Conditions: Type 2 Diabetes Treated With Insulin
Interventions: Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS), Continuous Glucose Monitor (CGM) + Usual Care; Other
Lead sponsor: Daniel Chernavvsky, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin 5mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Birmingham, Alabama • Long Beach, California • North Hollywood, California + 12 more

Conditions: Type 2 Diabetes
Interventions: 2S, 4R Ketoconazole (DIO-902); Drug
Lead sponsor: DiObex; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Omaha, Nebraska • Portland, Oregon + 2 more

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 60
States / cities: Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Use of a PDA to assist shared decision making; Behavioral
Lead sponsor: EPI-Q; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Oak Brook, Illinois

Conditions: Hypogonadism
Interventions: testosterone, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, RO5027838, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Chula Vista, California • Miami, Florida

Conditions: Diabetes
Interventions: Blood glucose meter, Eversense CGM System; Device
Lead sponsor: Senseonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 23
States / cities: Los Angeles, California • Englewood, Colorado • Hamden, Connecticut + 20 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Hyperinsulinemic-euglycemic clamp; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Food Insecurity, Type 2 Diabetes Mellitus (T2DM), Hypertension
Interventions: Medically Tailored Meals, Grocery Prescription, Medically Tailored Meals and Grocery Prescription, Nutritional Counseling; Behavioral
Lead sponsor: Alison Gustafson; Other
Eligibility: 6 Years to 64 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more

Conditions: Hypertension, Hypertension Complicated With Type 2 Diabetes
Interventions: iTHRIVE intervention, Active comparator; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peripheral Artery Disease, Type 2 Diabetes
Interventions: Aspirin, Ticagrelor, Aspirin Placebo, Ticagrelor Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes, Renal Impairment
Interventions: PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Tampa, Florida • Saint Paul, Minnesota

Conditions: Dyslipidemia
Interventions: AZD8233 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Chula Vista, California • Glendale, California • La Mesa, California + 4 more

Conditions: Type 2 Diabetes, Hypertension
Interventions: amlodipine, hydralazine, terazosin or hydrochlorothiazide; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, long acting release, exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 24
States / cities: Encino, California • La Jolla, California • San Diego, California + 21 more

Conditions: Diabetes Mellitus, Overweight, Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Escondido, California • Lomita, California + 12 more

Conditions: Type 2 Diabetes
Interventions: INCB013739, Placebo comparator matching INCB013739, Metformin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Artesia, California • Calabasas, California + 54 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more

Conditions: Diabetes Mellitus, Type 2
Interventions: MANAGe-DM - novel nurse case management, Monthly Educational Mailing; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 2 Diabetes, Hyperlipidemia
Interventions: Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more

Conditions: Diabetes Mellitus, Obesity
Interventions: PF-07081532, Placebo, Rybelsus; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 39
States / cities: Centreville, Alabama • Anaheim, California • Canoga Park, California + 33 more

Conditions: Hypertension, Diabetic Nephropathies
Interventions: telmisartan, losartan; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 47
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Lancaster, California + 41 more

Search by objective public record fields.

Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Validation of a Patient Decision Aid for Type 2 Diabetes

Testosterone Replacement in Men With Diabetes and Obesity

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Eversense® Non-adjunctive Use Post Approval Study

Metabolomic Analysis of Hepatic Insulin Resistance

Food Insecurity, Social Determinants of Health

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

Integrating Free-choice Marketplace, dieTitian coacHing, cultuRally Tailored messagIng to improVE Blood Pressure

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)